Stifel Nicolaus Begins Coverage on Pyxis Oncology (NASDAQ:PYXS)

Stifel Nicolaus began coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a report published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

A number of other research firms have also recently weighed in on PYXS. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, May 16th. Jefferies Financial Group restated a buy rating and issued a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Pyxis Oncology presently has an average rating of Buy and an average target price of $9.00.

Pyxis Oncology Stock Down 5.5 %

Shares of PYXS opened at $3.29 on Thursday. The company has a market capitalization of $193.75 million, a price-to-earnings ratio of -2.42 and a beta of 1.29. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The stock’s 50-day moving average price is $3.44 and its 200-day moving average price is $4.23.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.19. The company had revenue of $16.15 million during the quarter, compared to analysts’ expectations of $4.25 million. As a group, equities analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the 2nd quarter worth about $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology in the first quarter valued at approximately $59,000. Cetera Advisors LLC acquired a new stake in shares of Pyxis Oncology in the first quarter worth approximately $100,000. Schulhoff & Co. Inc. increased its position in shares of Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after purchasing an additional 20,901 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.